HEALTH TIPS.: The US FDA has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD).

Monday, 25 November 2019

The US FDA has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD).

The US FDA has granted psilocybin therapy a Breakthrough Therapy designation for the second time in a year, this time with a view on accelerating trials testing its efficacy treating major depressive disorder (MDD).

submitted by /u/mvea
[link] [comments]

from Health https://ift.tt/2qz4yVC
via IFTTT

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)